Information Provided By: 
Fly News Breaks for October 18, 2019
MRNS
Oct 18, 2019 | 08:31 EDT
Cantor Fitzgerald analyst Alethia Young assumed coverage of Marinus Pharmaceuticals with an Overweight rating and $7 price target. The company's lead asset, ganaxalone, is currently in two Phase 3 studies and another is planned to start in 2020 and she thinks expectations are low for all three programs. She is most focused on refractory status epilepticus, or RSE, as an underappreciated opportunity, but also notes that Marinus could launch ganaxolone in CDKL5 deficiency disorder as early as 2021.
News For MRNS From the Last 2 Days
There are no results for your query MRNS
